US Pharma MarketingAffinia Therapeutics receives FDA orphan drug designation for AFTX-201
Affinia Therapeutics receives FDA orphan drug designation for AFTX-201 is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, a treatment in development for BAG3-associated DCM.
Source: Pharmaceutical Technology